scholarly journals The Use of Poly(N-vinyl pyrrolidone) in the Delivery of Drugs: A Review

Polymers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1114 ◽  
Author(s):  
Paola Franco ◽  
Iolanda De Marco
Keyword(s):  
Drug Delivery ◽  
Process Parameters ◽  
Active Compound ◽  
Vinyl Pyrrolidone ◽  
Hydrophilic Polymer ◽  
Synthetic Origin ◽  
Natural And Synthetic

Polyvinylpyrrolidone (PVP) is a hydrophilic polymer widely employed as a carrier in the pharmaceutical, biomedical, and nutraceutical fields. Up to now, several PVP-based systems have been developed to deliver different active principles, of both natural and synthetic origin. Various formulations and morphologies have been proposed using PVP, including microparticles and nanoparticles, fibers, hydrogels, tablets, and films. Its versatility and peculiar properties make PVP one of the most suitable and promising polymers for the development of new pharmaceutical forms. This review highlights the role of PVP in drug delivery, focusing on the different morphologies proposed for different polymer/active compound formulations. It also provides detailed information on active principles and used technologies, optimized process parameters, advantages, disadvantages, and final applications.

A comparative study of dissolving hyaluronic acid microneedles with trehalose and poly(vinyl pyrrolidone) for efficient peptide drug delivery

2018 ◽  
Vol 6 (10) ◽  
pp. 2566-2570 ◽  
Author(s):  
Hong Kee Kim ◽  
Soo Hyeon Lee ◽  
Boo Yong Lee ◽  
Sung Jin Kim ◽  
Chang Yub Sung ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Hyaluronic Acid ◽  
Comparative Study ◽  
Vinyl Pyrrolidone ◽  
Peptide Drug ◽  
Pharmacokinetic Properties ◽  
Poly Vinyl Pyrrolidone

We studied the role of the additives trehalose and poly(vinyl pyrrolidone) in the physical and pharmacokinetic properties of peptide drug incorporated microneedles.

The Role of Scanning Probe Microscopy in Drug Delivery Research

1996 ◽  
Vol 13 (3-4) ◽  
pp. 225-256 ◽  
Author(s):  
Kevin M. Shakesheff ◽  
Martyn C. Davies ◽  
Clive J. Roberts ◽  
Saul J. B. Tendler ◽  
Philip M. Williams
Keyword(s):  
Drug Delivery ◽  
Scanning Probe Microscopy ◽  
Scanning Probe ◽  
Probe Microscopy

Role of Polymers in Exploring Modified and Sustained Release for Intradermal Drug Delivery

2020 ◽  
Vol 23 (15) ◽  
Author(s):  
Ritika Puris ◽  
Chandan Sharma ◽  
Dr. Manish Goswami
Keyword(s):  
Drug Delivery ◽  
Sustained Release

Emerging Role of Colloidal Drug Delivery Systems (CDDS) in NSAID Topical Administration

2013 ◽  
Vol 20 (14) ◽  
pp. 1847-1857 ◽  
Author(s):  
Carmelo Puglia ◽  
Giorgia Tirendi ◽  
Francesco Bonina
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Topical Administration ◽  
Delivery Systems

The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery

2016 ◽  
Vol 22 (9) ◽  
pp. 1259-1273 ◽  
Author(s):  
Carolyn Jordan ◽  
Vladimir V. Shuvaev ◽  
Mark Bailey ◽  
Vladimir R. Muzykantov ◽  
Thomas D. Dziubla
Keyword(s):  
Drug Delivery ◽  
Biological Barriers

Monocyte as an Emerging Tool for Targeted Drug Delivery: A Review

2019 ◽  
Vol 24 (44) ◽  
pp. 5296-5312 ◽  
Author(s):  
Fakhara Sabir ◽  
Rai K. Farooq ◽  
Asim.ur.Rehman ◽  
Naveed Ahmed
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
The Body ◽  
Carrier System ◽  
Bone Marrow Precursor ◽  
Extensive Introduction ◽  
Cancer Inflammation ◽  
Targeted Drug ◽  
Cluster Of Differentiation

Monocytes are leading component of the mononuclear phagocytic system that play a key role in phagocytosis and removal of several kinds of microbes from the body. Monocytes are bone marrow precursor cells that stay in the blood for a few days and migrate towards tissues where they differentiate into macrophages. Monocytes can be used as a carrier for delivery of active agents into tissues, where other carriers have no significant access. Targeting monocytes is possible both through passive and active targeting, the former one is simply achieved by enhanced permeation and retention effect while the later one by attachment of ligands on the surface of the lipid-based particulate system. Monocytes have many receptors e.g., mannose, scavenger, integrins, cluster of differentiation 14 (CD14) and cluster of differentiation 36 (CD36). The ligands used against these receptors are peptides, lectins, antibodies, glycolipids, and glycoproteins. This review encloses extensive introduction of monocytes as a suitable carrier system for drug delivery, the design of lipid-based carrier system, possible ways for delivery of therapeutics to monocytes, and the role of monocytes in the treatment of life compromising diseases such as cancer, inflammation, stroke, etc.

Role of Exosomes in the Exchange of Spermatozoa after Leaving the Seminiferous Tubule: A Review

2020 ◽  
Vol 21 (5) ◽  
pp. 330-338
Author(s):  
Luming Wu ◽  
Yuan Ding ◽  
Shiqiang Han ◽  
Yiqing Wang
Keyword(s):  
Drug Delivery ◽  
Plasma Membrane ◽  
Seminiferous Tubule ◽  
Metabolic Diseases ◽  
Inflammatory Diseases ◽  
Multivesicular Bodies ◽  
Extensive Search ◽  
Neurological Research ◽  
The One

Background: Exosomes are extracellular vesicles (EVs) released from cells upon fusion of an intermediate endocytic compartment with the plasma membrane. They refer to the intraluminal vesicles released from the fusion of multivesicular bodies with the plasma membrane. The contents and number of exosomes are related to diseases such as metabolic diseases, cancer and inflammatory diseases. Exosomes have been used in neurological research as a drug delivery tool and also as biomarkers for diseases. Recently, exosomes were observed in the seminal plasma of the one who is asthenozoospermia, which can affect sperm motility and capacitation. Objective: The main objective of this review is to deeply discuss the role of exosomes in spermatozoa after leaving the seminiferous tubule. Methods: We conducted an extensive search of the literature available on relationships between exosomes and exosomes in spermatozoa on the bibliographic database. Conclusion: : This review thoroughly discussed the role that exosomes play in the exchange of spermatozoa after leaving the seminiferous tubule and its potential as a drug delivery tool and biomarkers for diseases as well.

PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence

2019 ◽  
Vol 20 (12) ◽  
pp. 1217-1226 ◽  
Author(s):  
Arunaksharan Narayanankutty
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Therapeutic Target ◽  
Clinical Evidence ◽  
Mtor Pathway ◽  
Colorectal Cancers ◽  
Patent Literature ◽  
Mtor Signalling ◽  
Natural And Synthetic

Background: Phosphoinositide 3-kinase (PI3Ks) is a member of intracellular lipid kinases and involved in the regulation of cellular proliferation, differentiation and survival. Overexpression of the PI3K/Akt/mTOR signalling has been reported in various forms of cancers, especially in colorectal cancers (CRC). Due to their significant roles in the initiation and progression events of colorectal cancer, they are recognized as a striking therapeutic target. Objective: The present review is aimed to provide a detailed outline on the role of PI3K/Akt/mTOR pathway in the initiation and progression events of colorectal cancers as well as its function in drug resistance. Further, the role of PI3K/Akt/mTOR inhibitors alone and in combination with other chemotherapeutic drugs, in alleviating colorectal cancer is also discussed. The review contains preclinical and clinical evidence as well as patent literature of the pathway inhibitors which are natural and synthetic in origin. Methods: The data were obtained from PubMed/Medline databases, Scopus and Google patent literature. Results: PI3K/Akt/mTOR signalling is an important event in colorectal carcinogenesis. In addition, it plays significant roles in acquiring drug resistance as well as metastatic initiation events of CRCs. Several small molecules of natural and synthetic origin have been found to be potent inhibitors of CRCs by effectively downregulating the pathway. Data from various clinical studies also support these pathway inhibitors and several among them are patented. Conclusion: Inhibitors of the PI3K/mTOR pathway have been successful for the treatment of primary and metastatic colorectal cancers, rendering the pathway as a promising clinical cancer therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document